Recent Posts
- HealthInvest June 2026: A Look Inside Australia's Healthcare Innovations16 Jun 2026
- HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences19 May 2026
- Lifesaving Capital: How impact investing is shaping the future of biotech30 Apr 2026
- Investor Relations: the quiet advantage powering ASX microcaps28 Nov 2025
- HealthInvest Sydney: Life Sciences in the Investor Spotlight06 Oct 2025
Archives
Servatus launches new trial into the effects of live biotherapeutics on insomnia

Servatus CEO Dr Wayne Finlayson discusses the company’s new human clinical trial into the link between the gut microbiome and sleep by treating patients who suffer from insomnia with live biotherapeutics
